TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
September 30 2021 - 4:01PM
Business Wire
TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an
emerging RNA oncology company created on the belief that cancer can
be defeated through the intelligent design and effective delivery
of RNA therapeutics, today announced that Zdravka Medarova, Ph.D.,
has been appointed as the company’s Chief Technology Officer
effective October 1, 2021. Dr. Medarova is a scientific co-founder
of TransCode and has served as a member of TransCode’s advisory
board since its founding in January 2016.
“We are delighted to welcome Zdravka as a full-time member of
the TransCode team,” said Michael Dudley, CEO of TransCode. “We
have long benefitted from her extensive expertise in developing
nanotechnology and imaging tools to better understand cancer
initiation and progression, as well as her support of our
preclinical research through affiliations with Harvard Medical
School and Massachusetts General Hospital. Zdravka’s leadership
will be invaluable as we pursue validation of our TTX platform as a
viable means to bring the promise of RNA therapeutics to the
treatment of cancer.”
Dr. Medarova joins TransCode from Harvard Medical School and
Massachusetts General Hospital (MGH), where she served as an
Associate Professor of Radiology at Harvard Medical School and an
Assistant in Neuroimaging at the Athinoula A. Martinos Center for
Biomedical Imaging at MGH. Dr. Medarova carried out seminal work in
the field of RNA oncology. Together with her colleagues at MGH, she
described, for the first time, the design and application of iron
oxide nanoparticles as imaging-capable carriers of siRNA to tumors.
This work generated substantial interest in the research community
since it illustrated the value of these nanoparticles for
delivering small RNA therapy for oncology applications and
described an approach for the noninvasive monitoring of RNA
delivery. Since then, Dr. Medarova has emerged as one of the
leaders in the field of non-coding RNA delivery to cancer. She has
developed a robust NIH funded program and authored multiple
high-impact publications on the topic of RNA delivery,
nanotechnology, and the biology of cancer metastasis.
Dr. Medrova obtained a B.A. in pre-medicine from the University
of Southerin Maine and a Ph.D. in Genetics from the University of
New Hamspshire.
“As one of TransCode’s scientific co-founders, in addition to
supporting the company as a researcher and advisor, I have had
significant exposure to the company’s TTX delivery platform and
lead candidate, TTX-MC138,” said Dr. Medarova. “Across this
experience, I believe TransCode’s approach may finally solve the
persistent challenge of RNA delivery in oncology with the potential
for tremendous patient impact. I am eager to join TransCode at this
important time in the company’s growth, with first-in-human studies
and clinical assessment on the horizon, to help bring TransCode’s
technology to its fullest potential.”
Dr. Medarova has been invited to present at the upcoming
International Oligonucleotide and Peptide Conference (IOPC) on
October 18-19, 2021. Her talk, “The Future of Oncology Through the
Lens of RNA,” will support TransCode’s approach to RNA delivery
using its TTX platform technology.
About TransCode Therapeutics
TransCode is an emerging RNA oncology company created on the
belief that cancer can be defeated through the intelligent design
and effective delivery of RNA therapeutics. The Company has created
a platform of drug candidates designed to target a variety of tumor
types with the objective of significantly improving patient
outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is
focused on treating metastatic cancer, which causes approximately
90% of all cancer deaths representing over nine million deaths per
year worldwide. The Company believes that TTX-MC138 has the
potential to produce regression without recurrence in a range of
cancers, including breast, pancreatic, ovarian and colon cancer,
glioblastomas and others. The Company’s other drug candidates,
TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by
targeting PD-L1 and Lin28b, respectively. The Company is also
developing diagnostic products related to its planned therapeutics
business.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, without limitation, statements concerning the
therapeutic potential of TTX-MC138 and statements concerning
TransCode’s development programs and TTX technology platform
generally. Any forward-looking statements in this press release are
based on management’s current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: the risk
associated with drug discovery and development; the risk that the
results of our planned clinical trials will not be consistent with
our pre-clinical studies or expectations; risks associated with the
timing and outcome of TransCode's planned regulatory submissions;
risks associated with TransCode’s planned clinical trials for its
product candidates; risks associated with obtaining, maintaining
and protecting intellectual property; risks associated with
TransCode’s ability to enforce its patents against infringers and
defend its patent portfolio against challenges from third parties;
the risk of competition from other companies developing products
for similar uses; risks associated with TransCode’s financial
condition and its need to obtain additional funding to support its
business activities, including TransCode’s ability to continue as a
going concern; risks associated with TransCode’s dependence on
third parties; and risks associated with the COVID-19 coronavirus.
For a discussion of these and other risks and uncertainties, and
other important factors, any of which could cause TransCode’s
actual results to differ from those contained in or implied by the
forward-looking statements, see the section entitled “Risk Factors”
in TransCode’s Quarterly Report on Form 10-Q for the period ended
June 30, 2021, as well as discussions of potential risks,
uncertainties and other important factors in TransCode’s subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release;
TransCode undertakes no duty to update this information unless
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210930005872/en/
Investor Contact: Josh Rappaport Stern Investor Relations
josh.rappaport@sternir.com
Company Contact: Tom Fitzgerald, CFO
tom.fitzgerald@transcodetherapeutics.com
TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Sep 2023 to Sep 2024